Intas Pharmaceuticals Limited – FDA 483, Jan 24, 2024

During an inspection conducted from January 15 to January 24, 2024, the FDA issued a Form 483 to Intas Pharmaceuticals Limited in Dehradun, Uttarakhand, India, a drug product manufacturer. The inspection revealed eight significant observations concerning the firm's adherence to Good Manufacturing Practices.

Key issues included serious deficiencies in investigating Out-of-Specification (OOS) and Out-of-Trend (OOT) results, where root causes were not scientifically supported, and appropriate corrective actions were often absent. Several batches with stability issues or process validation discrepancies were released to the U.S. market without sufficient investigation or remediation. The Quality Control unit exhibited inadequate oversight, including instances of laboratory data misrepresentation and a lack of proper audit trail review for standalone instruments.

Furthermore, the facility's aseptic processing areas showed critical shortcomings. The cleaning process for aseptic filling areas lacked validation, and appropriate sporicidal agents were not consistently used. Environmental monitoring protocols were deficient, with personnel gowns in critical aseptic areas held to lower microbial specifications and non-viable particle monitoring performed only under static conditions. Process simulation studies (media fills) failed to challenge worst-case intervention scenarios, compromising assurance of sterility. Additionally, bacterial endotoxin testing procedures were not strictly followed by laboratory personnel. Finally, batch production records lacked clear attribution of significant steps, and the firm did not adequately verify supplier test results for critical sterile components like vial stoppers, potentially impacting product quality. Intas Pharmaceuticals is required to address these observations with comprehensive corrective actions.